3 Stocks Driving The Health Services Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 91 points (0.6%) at 16,492 as of Wednesday, May 7, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,744 issues advancing vs. 1,239 declining with 163 unchanged.

The Health Services industry currently sits down 0.9% versus the S&P 500, which is up 0.3%. Top gainers within the industry include Humana ( HUM), up 4.1%, Hologic ( HOLX), up 2.0%, Fresenius Medical Care AG & Co. KGaA ( FMS), up 1.4% and Cigna ( CI), up 1.0%. On the negative front, top decliners within the industry include Novadaq Technologies ( NVDQ), down 14.0%, Boston Scientific ( BSX), down 1.2%, HCA Holdings ( HCA), down 1.0% and Medtronic ( MDT), down 0.6%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Thermo Fisher Scientific ( TMO) is one of the companies pushing the Health Services industry higher today. As of noon trading, Thermo Fisher Scientific is up $0.87 (0.8%) to $115.29 on light volume. Thus far, 580,601 shares of Thermo Fisher Scientific exchanged hands as compared to its average daily volume of 2.5 million shares. The stock has ranged in price between $113.65-$115.40 after having opened the day at $114.60 as compared to the previous trading day's close of $114.42.

Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics in the United States and internationally. Thermo Fisher Scientific has a market cap of $45.8 billion and is part of the health care sector. Shares are up 2.8% year-to-date as of the close of trading on Tuesday. Currently there are 13 analysts who rate Thermo Fisher Scientific a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Thermo Fisher Scientific as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, growth in earnings per share, compelling growth in net income and reasonable valuation levels. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Thermo Fisher Scientific Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Jim Cramer: Agilent Technology Has Been One of My Favorites

Secondaries Get Primary Attention; Discerning Market -- Cramer's Top Thoughts

Cramer: Secondary Offerings Get Primary Attention

The Stock Market Is on Fire, Especially in These Sectors: Market Recon

PerkinElmer Among Targets Fitting Thermo Fisher's M&A Criteria